Logo image of RVPH

REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Fundamental Analysis

USA - NASDAQ:RVPH - US76152G1004 - Common Stock

0.84 USD
+0.17 (+25.5%)
Last: 10/7/2025, 7:42:50 PM
0.7826 USD
-0.06 (-6.83%)
After Hours: 10/7/2025, 7:42:50 PM
Fundamental Rating

0

RVPH gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of RVPH have multiple concerns. RVPH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RVPH has reported negative net income.
In the past year RVPH has reported a negative cash flow from operations.
RVPH had negative earnings in 4 of the past 5 years.
In the past 5 years RVPH always reported negative operating cash flow.
RVPH Yearly Net Income VS EBIT VS OCF VS FCFRVPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

RVPH has a worse Return On Assets (-233.02%) than 90.82% of its industry peers.
Industry RankSector Rank
ROA -233.02%
ROE N/A
ROIC N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
RVPH Yearly ROA, ROE, ROICRVPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

RVPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVPH Yearly Profit, Operating, Gross MarginsRVPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, RVPH has more shares outstanding
Compared to 5 years ago, RVPH has more shares outstanding
The debt/assets ratio for RVPH is higher compared to a year ago.
RVPH Yearly Shares OutstandingRVPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RVPH Yearly Total Debt VS Total AssetsRVPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

RVPH has an Altman-Z score of -25.96. This is a bad value and indicates that RVPH is not financially healthy and even has some risk of bankruptcy.
RVPH has a worse Altman-Z score (-25.96) than 84.69% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -25.96
ROIC/WACCN/A
WACCN/A
RVPH Yearly LT Debt VS Equity VS FCFRVPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.90 indicates that RVPH may have some problems paying its short term obligations.
RVPH's Current ratio of 0.90 is on the low side compared to the rest of the industry. RVPH is outperformed by 84.18% of its industry peers.
RVPH has a Quick Ratio of 0.90. This is a bad value and indicates that RVPH is not financially healthy enough and could expect problems in meeting its short term obligations.
RVPH's Quick ratio of 0.90 is on the low side compared to the rest of the industry. RVPH is outperformed by 77.04% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.9
RVPH Yearly Current Assets VS Current LiabilitesRVPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

RVPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RVPH will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.15% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y48.66%
EPS Next 2Y23.21%
EPS Next 3Y18.85%
EPS Next 5Y14.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RVPH Yearly Revenue VS EstimatesRVPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
RVPH Yearly EPS VS EstimatesRVPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RVPH. In the last year negative earnings were reported.
Also next year RVPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVPH Price Earnings VS Forward Price EarningsRVPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVPH Per share dataRVPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

RVPH's earnings are expected to grow with 18.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.21%
EPS Next 3Y18.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RVPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVIVA PHARMACEUTICALS HOLDI

NASDAQ:RVPH (10/7/2025, 7:42:50 PM)

After market: 0.7826 -0.06 (-6.83%)

0.84

+0.17 (+25.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners21.06%
Inst Owner Change0%
Ins Owners5.17%
Ins Owner Change0%
Market Cap80.93M
Analysts81.82
Price Target5.95 (608.33%)
Short Float %20.63%
Short Ratio3.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.61%
Min EPS beat(2)-6.95%
Max EPS beat(2)30.16%
EPS beat(4)3
Avg EPS beat(4)13.79%
Min EPS beat(4)-6.95%
Max EPS beat(4)31.6%
EPS beat(8)6
Avg EPS beat(8)10.88%
EPS beat(12)8
Avg EPS beat(12)-2.48%
EPS beat(16)11
Avg EPS beat(16)0.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-30.79%
PT rev (3m)-38.13%
EPS NQ rev (1m)7.27%
EPS NQ rev (3m)18.4%
EPS NY rev (1m)10.2%
EPS NY rev (3m)9.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -233.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.9
Quick Ratio 0.9
Altman-Z -25.96
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.85%
EPS Next Y48.66%
EPS Next 2Y23.21%
EPS Next 3Y18.85%
EPS Next 5Y14.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.89%
OCF growth 3YN/A
OCF growth 5YN/A